Company Overview of IGXBio, Inc.
IGXBio, Inc., a biotechnology company, develops DNA immunotherapies for HIV infection. Its DNA immunotherapies reduce dependency on anti-HIV drug cocktails and diminish the emergence of drug-resistant HIV strains. The company offers GenePro (?4SHIVku2), a DNA therapeutic incorporating a DNA composition that yields high levels of gene expression and non-infectious HIV protein production, and induces an antibody and cellular immune response in animal models, including non-human primates. It’s therapeutic DNA vaccine generates viral like particles to allow the body to develop killer T cells and memory T cells related to HIV. IGXBio, Inc. was formerly known as ImmunoGenetix Therapeutics, Inc. Th...
8527 Bluejacket Street
Lenexa, KS 66214
Founded in 2001
Key Executives for IGXBio, Inc.
Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.
IGXBio, Inc. Key Developments
Cannabis Science and IGXBio Sign Collaborative Drug Development Deal
Nov 4 15
Cannabis Science announced that the company has signed a collaborative drug development deal with IGXBio and its GenePro. Both firms will produce joint protocols that explore potential synergistic effects of their respective drug candidates and potential new drug candidate opportunities. IGXBio has a drug called GenePro®, which is already registered with the FDA and has an IND number. This accelerates the process to seek FDA approval in the future. GenePro is aimed at promoting an anti-HIV immune response that facilitates virus control in HIV-infected subjects.
Cannabis Science, Inc. Enters into Joint Development Agreement with IGXBio, Inc
May 27 15
On May 21, 2015, Cannabis Science, Inc. (the Company), entered into a Joint Development Agreement with IGXBio, Inc., a Delaware corporation (IGXB). Pursuant to the Agreement the Company and IGXB will jointly develop and conduct a clinical protocol for an anti-inflammatory utilizing cannabinoids and GenePro, a DNA based immunotherapy with a FDA IND number. Each company will retain ownership of their respective intellectual property and equally own any new products or drugs derived from the Agreement. The term of the Agreement is initially for 4 years with an automatic renewal provision. The Company will issue IGXB 5 million shares of restricted common stock pursuant to the Agreement.
IGXBio, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:00 AM
Nov 20 14
IGXBio, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:00 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|